Get to know our clinical trials

Clinical trial of the SHP2 inhibitor BBP-398 (formerly known as IACS-15509) in combination with the KRAS-G12C inhibitor sotorasib in patients with advanced solid tumors and a KRAS-G12C mutation.

THE AIM OF THIS STUDY IS TO FIND THE BEST DOSE OF BBP-398 IN COMBINATION WITH SOTORASIB AND TO KNOW THE EFFECTS (GOOD AND BAD) THAT THIS COMBINATION HAS IN PEOPLE WITH NON-SMALL CELL LUNG CANCER (NSCLC) OR LOCALLY ADVANCED OR METASTATIC SOLID TUMOR WITH A GENETIC MUTATION IN KRAS-G12C.

Status
In recruitment
headquarters
Pamplona/Madrid

Technical Summary

  • PHASE I STUDY OF THE SHP2 INHIBITOR BBP-398 (FORMERLY KNOWN AS IACS-15509) IN COMBINATION WITH THE KRAS-G12C INHIBITOR SOTORASIB IN PATIENTS WITH ADVANCED SOLID TUMORS AND A KRAS-G12C MUTATION.
  • Code EudraCT: 2022-000379-38
  • Protocol number: NAV-1003
  • Promoter: Navire Pharma Inc.
  • Molecule/Drug: inhibidor BBP-398 de SHP2 y sotorasib

* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.

More information about this clinical trial

Information offered by the Spanish Registry of Clinical Studies

  • Summary
  • Information
  • Calendar
  • Headquarters
  • Drugs
Imagen de un icono azul con un fonendoscopio o estetoscopio.

Do you want to participate in this trial?

Request an appointment for our specialists to assess whether you qualify for this clinical trial


Imagen de un icono azul de un registro en el informe médico.

Do you prefer to send us your reports?

If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.